Navigation Links
CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
Date:1/5/2012

COPENHAGEN, Denmark and SEATTLE, Jan. 5, 2012 /PRNewswire/ -- CMC Biologics, a leading biopharmaceutical contract manufacturing organization, announced the issuance of European Patent No. US 2,171,034 B1 covering a method for improving productivity in microbial fermentations and mammalian cell culture bioreactors. The invention is designed to optimize production of a biotherapeutic in a continuous perfusion fermentation process, wherein the bioreactor (fermenter) has an ultrafiltration system that allows impurities to be removed while retaining cells in the bioreactor.

(Logo:  http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"CMC Biologics is continually innovating to advance biopharmaceutical manufacturing to the next level. Our expertise in developing efficient production processes puts our clients' projects in an optimal position to succeed," said Mads Laustsen, Chief Scientific Officer of CMC Biologics and Inventor.  "This proprietary technology demonstrates that using the impurity filter improved cell density, productivity and product concentration – all critical to helping our customers move their products to market on time and on target."

 

Perfusion bioreactors involve continuous cell culture, feeding, and withdrawal (harvesting) of product and accumulates no waste products, thereby creating a stable cell growth environment.  Optimal environmental conditions can be precisely controlled with this new technology resulting in increased productivity due to increased cell density in the reactor and in particular, a significant higher concentration of the product in the harvested medium. The expressed biologics are rapidly removed and made available for purification at high concentration — a significant advantage for the downstream processing.

 

About CMC Biologics

CMC Biologics (www.cmcbio.com) is a global contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.

 

 


 


'/>"/>
SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
2. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
3. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
4. Savient Submits Biologics License Application (BLA) for pegloticase
5. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
6. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
7. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
8. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
9. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
10. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
11. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ca (PRWEB) , ... October 12, 2017 , ... ... the Surgical Wound Market with the addition of its newest module, US Hemostats ... $1.2B market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic ...
(Date:10/11/2017)... ... ... a basic first aid supply for any work environment, but most personal eye wash can ... a dangerous substance enters both eyes? It’s one less decision, and likely quicker response time ... , “Whether its dirt and debris, or an acid or alkali, getting anything in your ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
Breaking Biology News(10 mins):